Adaptive Biotechnologies Raises FY 2026 MRD Revenue Forecast to $276 Million-$286 Million

Bitget2026/11/04 22:53

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adaptive Biotechnologies raised fiscal 2026 MRD revenue guidance to $276 million-$286 million from $268 million-$278 million.
Operating expenses are now forecast at approximately $350 million, versus the previous range of $350 million-$355 million.
The revenue outlook includes $9 million in MRD milestones, all recognized in the first quarter.
Clinical volumes and pharma drove the increase; third-quarter MRD revenue grew 44% year over year excluding milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Adaptive Biotechnologies Raises FY 2026 MRD Revenue Forecast to $276 Million-$286 Million

You may also like

Crypto prices